Holen Sie sich die Stockscreener-App
89.66
4.44%
-4.17
Handel nachbörslich:
87.87
-1.79
-2.00%
Schlusskurs vom Vortag:
$93.83
Offen:
$92.68
24-Stunden-Volumen:
1.07M
Relative Volume:
0.55
Marktkapitalisierung:
$11.76B
Einnahmen:
$982.02M
Nettoeinkommen (Verlust:
$-416.28M
KGV:
-27.05
EPS:
-3.3148
Netto-Cashflow:
$-233.07M
1W Leistung:
+4.01%
1M Leistung:
-1.69%
6M Leistung:
+41.46%
1J Leistung:
+120.95%
1-Tages-Spanne:
$89.48
$93.26
1-Wochen-Bereich:
$86.42
$96.30
52-Wochen-Spanne:
$36.36
$120.74
Guardant Health Inc Stock (GH) Company Profile
Firmenname
Guardant Health Inc
Sektor
Branche
Telefon
855-698-8887
Adresse
3100 HANOVER STREET, PALO ALTO
Compare GH vs TMO, DHR, IDXX, A, WAT
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
GH
Guardant Health Inc
|
89.66 | 12.31B | 982.02M | -416.28M | -233.07M | -3.3148 |
TMO
Thermo Fisher Scientific Inc
|
488.19 | 182.57B | 44.56B | 6.72B | 6.29B | 17.74 |
DHR
Danaher Corp
|
192.12 | 135.26B | 24.57B | 3.60B | 5.26B | 5.051 |
IDXX
Idexx Laboratories Inc
|
577.44 | 45.24B | 4.30B | 1.06B | 1.04B | 13.08 |
A
Agilent Technologies Inc
|
114.84 | 32.63B | 7.07B | 1.29B | 993.00M | 4.5355 |
WAT
Waters Corp
|
304.09 | 29.85B | 3.17B | 642.63M | 516.49M | 10.77 |
Guardant Health Inc Stock (GH) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2026-02-20 | Bestätigt | Canaccord Genuity | Buy |
| 2026-02-17 | Eingeleitet | Robert W. Baird | Outperform |
| 2026-01-05 | Herabstufung | Evercore ISI | Outperform → In-line |
| 2025-12-02 | Fortgesetzt | Morgan Stanley | Overweight |
| 2025-09-25 | Hochstufung | Wolfe Research | Peer Perform → Outperform |
| 2025-09-22 | Fortgesetzt | Wells Fargo | Overweight |
| 2025-04-10 | Eingeleitet | Mizuho | Outperform |
| 2025-01-23 | Eingeleitet | Barclays | Overweight |
| 2024-06-28 | Hochstufung | Guggenheim | Neutral → Buy |
| 2024-06-03 | Fortgesetzt | Jefferies | Buy |
| 2024-04-24 | Fortgesetzt | Craig Hallum | Buy |
| 2023-12-14 | Eingeleitet | Guggenheim | Neutral |
| 2023-12-13 | Eingeleitet | Wolfe Research | Peer Perform |
| 2023-11-13 | Hochstufung | Raymond James | Mkt Perform → Outperform |
| 2023-09-28 | Eingeleitet | Bernstein | Outperform |
| 2023-09-27 | Hochstufung | Piper Sandler | Neutral → Overweight |
| 2023-07-05 | Fortgesetzt | JP Morgan | Overweight |
| 2023-05-26 | Hochstufung | Citigroup | Neutral → Buy |
| 2023-05-05 | Eingeleitet | UBS | Buy |
| 2023-03-09 | Herabstufung | Citigroup | Buy → Neutral |
| 2023-01-05 | Eingeleitet | Scotiabank | Sector Outperform |
| 2022-11-01 | Herabstufung | Piper Sandler | Overweight → Neutral |
| 2022-10-19 | Eingeleitet | Craig Hallum | Buy |
| 2022-10-06 | Eingeleitet | Stephens | Overweight |
| 2022-08-25 | Eingeleitet | Credit Suisse | Outperform |
| 2022-06-03 | Eingeleitet | Piper Sandler | Overweight |
| 2022-04-28 | Fortgesetzt | BTIG Research | Buy |
| 2022-02-24 | Bestätigt | Canaccord Genuity | Buy |
| 2022-02-24 | Bestätigt | Citigroup | Buy |
| 2022-02-24 | Bestätigt | Cowen | Outperform |
| 2022-02-24 | Bestätigt | Morgan Stanley | Overweight |
| 2022-02-24 | Bestätigt | SVB Leerink | Outperform |
| 2022-02-24 | Bestätigt | Stifel | Buy |
| 2022-02-24 | Bestätigt | Wells Fargo | Overweight |
| 2021-10-15 | Fortgesetzt | Cowen | Outperform |
| 2021-06-15 | Eingeleitet | Raymond James | Mkt Perform |
| 2021-06-03 | Eingeleitet | Goldman | Buy |
| 2021-05-25 | Eingeleitet | Wells Fargo | Overweight |
| 2021-01-11 | Eingeleitet | Stifel | Buy |
| 2020-09-09 | Eingeleitet | Morgan Stanley | Overweight |
| 2020-06-12 | Eingeleitet | BTIG Research | Buy |
| 2020-02-21 | Eingeleitet | Guggenheim | Buy |
| 2020-01-07 | Eingeleitet | Citigroup | Buy |
| 2019-08-07 | Bestätigt | Canaccord Genuity | Buy |
| 2019-04-16 | Eingeleitet | Canaccord Genuity | Buy |
| 2019-04-10 | Hochstufung | BofA/Merrill | Neutral → Buy |
| 2019-02-28 | Bestätigt | BofA/Merrill | Neutral |
| 2018-10-29 | Eingeleitet | BofA/Merrill | Neutral |
| 2018-10-29 | Eingeleitet | JP Morgan | Overweight |
| 2018-10-29 | Eingeleitet | William Blair | Outperform |
Alle ansehen
Guardant Health Inc Aktie (GH) Neueste Nachrichten
[144] Guardant Health, Inc. SEC Filing - Stock Titan
Guardant Health (GH) Sees Price Target Reduction from Evercore I - GuruFocus
Guardant Health, Organon, Fortrea, QuidelOrtho, and Charles River Laboratories Stocks Trade Down, What You Need To Know - TradingView
Guardant Health, Inc. $GH is Capricorn Fund Managers Ltd's 6th Largest Position - marketbeat.com
SG Americas Securities LLC Invests $1.74 Million in Guardant Health, Inc. $GH - marketbeat.com
Guardant Health, Inc. (GH) stock price, news, quote and history - Yahoo Finance UK
Guardant Health, Inc. (GH) Stock Price, News, Quote & History - Yahoo! Finance Canada
Guardant Health real-world data supports Japan approval of ENHERTU for HER2-positive tumors - MSN
Guardant Health, Inc. (NASDAQ:GH) Receives Consensus Rating of "Moderate Buy" from Analysts - MarketBeat
Guardant Health (GH) Valuation Check After Strong 1 Year Return And Recent 90 Day Pullback - Yahoo Finance
Guardant Health, Inc. (GH) Stock forecasts - Yahoo Finance UK
Guardant Health Inc (5GH.MU) Stock Price, News, Quote & History - Yahoo! Finance Canada
Guardant Health (GH) partners with Manulife to launch Shield multi-cancer detection test in Asia - MSN
Guardant Health (NASDAQ: GH) CLO converts RSUs, withholds shares for taxes - Stock Titan
Guardant Health (GH) CPO gains stock from RSU vesting and tax withholding - Stock Titan
Guardant Health (NASDAQ: GH) CIO adds shares after RSU vesting - Stock Titan
11,213 Guardant Health (GH) RSUs vest; 4,750 shares withheld for tax - Stock Titan
Guardant Health (GH) CMO nets shares as RSUs vest and taxes withheld - Stock Titan
Guardant Health (GH) CTO nets new shares after RSU vesting and tax withholding - Stock Titan
Guardant Health (GH) CFO exercises 12,777 RSUs; 6,869 shares withheld for taxes - Stock Titan
Guardant Health (GH) Co-CEO Talasaz converts RSUs, withholds shares for taxes - Stock Titan
Guardant Health (GH) co-CEO reports RSU vesting, tax-share withholdings and over 2.1M shares held - Stock Titan
1 Healthcare Stock with Exciting Potential and 2 Facing Headwinds - Yahoo Finance
SWS Partners Has $7.89 Million Holdings in Guardant Health, Inc. $GH - marketbeat.com
Allspring Global Investments Holdings LLC Reduces Stock Holdings in Guardant Health, Inc. $GH - marketbeat.com
GH Stock Price, Quote & Chart | GUARDANT HEALTH INC (NASDAQ:GH) - ChartMill
Guardant Health Stock Rises on Japan Regulatory News for Daiichi Sankyo DrugNews and Statistics - IndexBox
Guardant Health (GH) Gains Momentum on Promising Outlook - GuruFocus
Director at Guardant Health (GH) acquires 155 shares via RSUs - Stock Titan
Quarterly Recap: Can Guardant Health Inc maintain its current growth rate2026 Institutional Moves & Smart Allocation Stock Reports - baoquankhu1.vn
Guardant Health gets oncology innovation accolade at Healthcare Asia Medtech Awards 2026 - Mugglehead Magazine
Why Is Guardant Health (GH) Stock Soaring Today - Yahoo Finance UK
Guardant Health (GH) and Verana Health Announces New Partnership - Insider Monkey
INVESCO Small Cap Equity Fund's Guardant Health Inc(GH) Holding History - GuruFocus
The Bull Case For Guardant Health (GH) Could Change Following Japan’s ENHERTU Approval Using Its AI Data - simplywall.st
Guardant Health (GH) Supports Approval of Cancer Treatment in Ja - GuruFocus
Guardant Health Inc (GH) Trading Down 3.96% on Mar 30 - gurufocus.com
Guardant Health's AI Data Supports ENHERTU Approval - National Today
Guardant Health's Infinityai real-world evidence supports approval of Enhertu® for previously treated patients with HER2-positive metastatic solid tumors in Japan - MarketScreener
Guardant Health’s InfinityAI Real-World Evidence Supports Approval of ENHERTU® for Previously Treated Patients with HER2-Positive Metastatic Solid Tumors in Japan - Business Wire
Liquid Biopsy Market Is Booming Rapidly with Strong Demand By 2033 | Guardant Health Inc., Foundation Medicine Inc. - openPR.com
Oncology Biomarkers Market Trends and Investment Opportunities Report 2026-2030: Global, Regional and Country-Level Outlook - GlobeNewswire Inc.
(GH) as a Liquidity Pulse for Institutional Tactics - Stock Traders Daily
5 High Growth Healthcare Stocks to Buy Now - Insider Monkey
GH PE Ratio & Valuation, Is GH Overvalued - intellectia.ai
Guardant Health to present new cancer research while stock trades lower amid strong sell signals - Traders Union
Finanzdaten der Guardant Health Inc-Aktie (GH)
Umsatz
Nettogewinn
Free Cashflow
ENV
0.47%
1.47%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):